Ironwood Pulls Plug On Struggling Gout Drug Zurampic
Executive Summary
Due to poor sales, the drug, which AstraZeneca picked up through its $1.26bn acquisition of Ardea, is now being terminated in the US. Ironwood, already in the process of splitting up, is going to focus on its core gastrointestinal franchise.
You may also be interested in...
Takeda’s Uloric Gets CV Death Warning And Restricted Indication, But No REMS
Despite advisory committee pressure, US FDA stands firm against imposing REMS targeted at gout drug’s cardiovascular risks; however, Takeda must conduct utilization study to see if labeling changes impact prescribing patterns.
Ironwood Being Split In Two: Is Move To Thwart Activist Investor Sarissa?
Move will spin out sGC assets into solo listed group while smaller Ironwood will focus on GI diseases and abdominal pain.
Duzallo Approval Opens Gout Opportunity For Ironwood
Pricing for Duzallo, a fixed-dose combination of Zurampic (lesinurad) with generic allopurinol, will likely be on par with Zurampic's solo price tag of $371 per month to smooth the way with payers.